108 results about "Myocyte proliferation" patented technology

Devices and methods for reducing, inhibiting, or treating restenosis and hyperplasia after intravascular intervention are provided. In particular, the present invention provides luminal prostheses which allow for sustained or controlled release of at least one therapeutic capable agent with increased efficacy to selected locations within a patient's vasculature to reduce restenosis. An intraluminal prosthesis may comprise an expandable structure and a source adjacent the expandable structure for releasing the therapeutic capable agent into a body lumen to reduce smooth muscle cell proliferation.

A stent is provided with a composition which includes melatonin and paclitaxel for use in treating smooth muscle cell proliferation, such as stenosis and preventing restenosis in vascular vessels.

The invention discloses a preparation method of a copper ion mediated anticoagulant coating with function of in situ catalysis of NO release. The method includes steps of preparing an acidic buffer solution, and adding a compound with pyrogallol structure and certain concentration, a compound with amino or thiol, and copper ion soluble salt. The method of the invention has the advantages of simple operation, mild reaction conditions and easiness. The prepared coating has the advantages of controllable content of the units containing multiple amino or thiol compounds, and easily controlled loading amount of copper ion. The modified coating prepared by the method has excellent adhesion with a base material, and through act of the copper ions in the coating with the blood, the coating can conduct in situ catalyze the NO donor molecules in blood to continuously decompose and release NO molecules, thus realizing the inhibition of platelet activation and aggregation, inhibiting smooth muscle cell proliferation and migration, and protecting vascular endothelial layer function.

Devices and methods for reducing, inhibiting, or treating restenosis and hyperplasia after intravascular intervention are provided. In particular, the present invention provides luminal prostheses which allow for sustained or controlled release of at least one therapeutic capable agent with increased efficacy to selected locations within a patient's vasculature to reduce restenosis. An intraluminal prosthesis may comprise an expandable structure and a source adjacent the expandable structure for releasing the therapeutic capable agent into a body lumen to reduce smooth muscle cell proliferation.

The present invention provides improved devices and methods for minimizing and/or inhibiting restenosis and hyperplasia after intravascular intervention. In particular, the present invention provides luminal prostheses which allow for programmed and controlled mycophenolic acid delivery with increased efficacy to selected locations within a patient's vasculature to inhibit restenosis. An intraluminal delivery prosthesis may comprise an expansible structure and means on or within the structure for releasing mycophenolic acid at a rate selected to inhibit smooth muscle cell proliferation.

Devices and methods for reducing, inhibiting, or treating restenosis and hyperplasia after intravascular intervention are provided. In particular, the present invention provides luminal prostheses which allow for controlled release of at least one therapeutic capable agent with increased efficacy to selected locations within a patient's vasculature to reduce restenosis. An intraluminal prosthesis may comprise an expandable structure and a source adjacent the expandable structure for releasing the therapeutic capable agent into a body lumen to reduce smooth muscle cell proliferation.

The invention discloses a preparation method of an anticoagulant material with function of inducing and catalyzing release of endogenous NO. The method comprises the steps of: configuring an alkaline Tris-buffer buffer solution, and adding a compound with certain concentration and pyrogallol structure and a compound with disulfide bond or diselenium bond and containing amino or thiol at two ends; and placing the substrate materials in a reaction solution, controlling the reaction temperature, reacting for 1-24 h, removing the substrate, and cleaning and drying to obtain the objective material. The invention has the advantages of simple operation, mild reaction conditions and easy operation. The component unit of the compound with disulfide bond or diselenium bond and containing amino or thiol at two ends has controllable content; the modified coating prepared by the method has excellent adhesion, and catalyzes the blood NO donors to continuously release NO molecules through in situ catalysis, inhibits activation and aggregation of platelets, inhibits proliferation of smooth muscle cells, and protects vascular endothelium.

Provided are devices and methods for treating or preventing smooth muscle cell proliferation caused by endothelin-mediated conditions. In particular, a medical device comprising a structure which is implantable within a body lumen and means on or within the structure for releasing an endothelin (A) receptor antagonist at a rate effective to inhibit smooth muscle cell proliferation. The device can be, for example, an expansible stent or a graft, and the means can include a matrix coating, wherein the endothelin (A) receptor antagonist can be dispersed within the coating or disposed directly on the structure and under the matrix. The methods and devices of this invention can be used to decrease the incidence of restenosis as well as other thromboembolic complications resulting from implantation of medical devices.

Compounds of formula (I), and methods and/or compositions comprising compounds that are effective in modulating inflammatory responses, such as those resulting from AGE and glycated protein accumulation are provided. Methods and/or compositions comprising compounds that are effective in modulating smooth muscle cell proliferation and the diseases or conditions related thereto are also provided.

A medicine coated scaffold for preventing and treating the renarrowing of arteria coronaria after plastic operation features that the tatin kind of medicines which can suppress the growth of new tunia intime and the reproduction of smooth muscle cells is contained in the coated layer of scaffold and can be slowly released to prevent said renarrowing of arteria coronaria. Its advantages are high effect and low cost.

The invention discloses a medicine-applying filming support. The medicine-applying filming support comprises a supporting body, an inner film and an outer film. The inner film is closely attached to an inner cavity of the support body and fixedly connected with the support body; filming areas are formed in the portions, provided with the inner film, of the support body, the outer film is wound around the support body relative to the outer surface of the filming areas, and the support body is firmly wrapped by the outer film in the middle of the inner film and the outer film; bare support areas are formed in the portions, not provided with the inner film, of the support body, and the bare support areas and the filming areas are sequentially and alternately arranged. According to the medicine-applying filming support, the bending performance of the filming support is improved through the filming mode; meanwhile, the wall attaching performance and the stability of the filming support are improved, and the problem that the filming support is prone to shifting is effectively solved. The inner cavity of the film is coated with anticoagulation medicine, and thrombosis is reduced; the whole outer wall of the filming support is loaded with medicine for inhibiting smooth-muscle-cell proliferation and migration, and restenosis of the inside and the two ends of the postoperation support cavity is effectively prevented.

The present invention provides improved devices and methods for minimizing and/or inhibiting restenosis and hyperplasia after intravascular intervention. In particular, the present invention provides luminal prostheses which allow for programmed and controlled methylprednisolone delivery with increased efficacy to selected locations within a patient's vasculature to inhibit restenosis. An intraluminal delivery prosthesis may comprise an expansible structure and means on or within the structure for releasing methylprednisolone into the body lumen to inhibit smooth muscle cell proliferation.

The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

The invention discloses a difunctional polymer nano-micelle, a preparation thereof and application in preparing a therapeutic drug for restenosis thereof. The difunctional polymer nano-micelle is prepared by the steps: (1) GPIIb/IIIa is connected on an amphiphilic block copolymer through amide linkage; (2) aqueous solution of the drug that improves vascular endothelial growth is injected into chloroform solution of the product prepared in step one to form even suspension; (3) the chloroform solution of the product prepared in step one is added into the chloroform solution of a drug inhibiting the proliferation of smooth muscle cells; (4) the solution prepared in step three is added into the even suspension prepared in step two, and then stirred and dried to form the difunctional polymer nano-micelle. The surface of the micelle is chemically coupled with platerlet membrane glocoprotein (GPIIb/IIIa) so as to really and specifically target the difunctional polymer nano-micelle to the hemadostenosis parts and provide a guarantee for directly acting the drug on lesion locations.

The invention discloses a Zn-Fe system zinc alloy and a preparation method and application thereof. The zinc alloy comprises Zn and Fe. The mass percentage of Fe in the zinc alloy is 0-10%, exclusive of 0. The zinc alloy further comprises a trace element, which is at least one of silicon, phosphorus, lithium, silver, tin and a rare earth element and has the mass percentage being 0-3%, exclusive of 0. The mechanical property of the Zn-Fe system zinc alloy conforms to the strength and toughness requirements of a medical implant material, is free of toxicity to endothelial cells and osteoblast, and can inhibit proliferation of smooth muscle cells. The Zn-Fe system zinc alloy is excellent in histocompatibility and blood compatibility and can be degraded by the body fluid through regulation and control. The dissolution metal ions can be absorbed and utilized through the living body or be excreted out of the body through metabolism. The zinc alloy is excellent in antibacterial performance and can be applied to preparation of a medical implant.